Virtual Event | December 19, 2022

The Importance of Vendor Selection

Source: Cytiva

Regarding vendor selection in support of allogeneic CAR-T therapy specifically, Gregory Opiteck, Ph.D., VP Head of Translational Sciences at Allogene Therapeutics covers top challenges, best practices, and expectations for the short term.

VIEW THE VIRTUAL EVENT!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online

Please tell us more about you so that we can customize our newsletters to your specific interests:

Cytiva